Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Not Yet Recruiting PHASE3 INTERVENTIONAL NCT06964334

The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

Helicobacter pylori (H. pylori) is one of the most common chronic infections worldwide. The mode of transmission of H. pylori is through the fecal-oral or oral-oral routes. Chronic gastritis has been linked to helicobacter pylori (H. pylori) infection. Peptic ulcer disease, gastric adenocarcinoma, and gastric lymphoma are all linked to this condition . In Egypt, a high prevalence of H. pylori infections has been reported, ranging from 70% in the general population , 73% among school children , up to 88% in patients with chronic active HCV . In 2007, the American College of Gastroenterology estimated that the cure rate for H. pylori infections was 70-85 percent with the use of a proton pump inhibitor (PPI), clarithromycin, and amoxicillin or metronidazole . children with H. pylori infection do not have severe digestive symptoms. pylori infection represents a key factor in the pathogenesis of duodenal ulcer and chronic gastritis in children. In addition, H. pylori infection has also been reported to have extra-digestive consequences . A recent comprehensive evaluation found that sequential and conventional triple treatment had a cure rate of 84% . The infected macrophage is unable to create enough 1,25-(OH)2D to control the synthesis of AMP cathelicidin when it is vitamin D deficient . vitamin D has a powerful systemic antibacterial impact by enhancing the activity of monocytes and macrophages. Most illnesses seem to benefit from a vitamin D-rich condition . Vitamin D-deficient subjects might be more prone to developing H. pylori infection .

Detailed Description

To assess the efficacy of adding vitamin D supplement as adjuvant therapy in eliminating helicobacter pylori infection.

Interventions

Name: Lansoprazole
Type: DRUG
Description: oral lansoprazole (1 mg/kg per day, max. 30 mg bid)for 14 day
Name: amoxicillin
Type: DRUG
Description: amoxicillin (50 mg/kg per day, max. 1 g bid) for 14 day
Name: clarithromycin
Type: DRUG
Description: oral clarithromycin (15 mg/kg per day, max. 500 mg bid) for 14 day
Name: vitamin D
Type: DRUG
Description: vitamin D therapy of 4000-5000 units daily in patients over 12 months old.

Primary Outcomes

Measure: cure rate after treatment
TimeFrame: 3 months
Description: compare cure rate between two groups

Trial Information

NCT ID

NCT06964334

Status

Not Yet Recruiting

Study Type

INTERVENTIONAL

Phases

PHASE3

Sponsor

Assiut University

Last Updated

December 15, 2025